Sherif S. Farag, MB,BS, PhD
- Address
-
Joseph E. Walther Hall, Room R3 414
980 W. Walnut St.
Indianapolis , IN 46202 - PubMed:
-
| Year | Degree | Institution |
|---|---|---|
| 1995 | PhD | University of Melbourne |
| 1984 | MB,BS | University of Melbourne |
a) Development of novel approaches to hematopoietic stem cell transplantation, including safer approaches to alternate donor transplantation through depletion of alloreactive T cells, utilization of KIR mismatches between donor and recipient, harnessing Treg cells, and NKT cells. b) Development of novel agents and regimens for the treatment of multiple myeloma. This includes pre-clinical research of novel agents (drug development).
High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation.
Farag SS; Nelson R; Cairo MS; O'Leary HA; Zhang S; Huntley C; Delgado D; Schwartz J; Zaid MA; Abonour R; Robertson M; Broxmeyer H; Oncotarget 2017 Nov 27
Farag SS; Nelson R; Cairo MS; O'Leary HA; Zhang S; Huntley C; Delgado D; Schwartz J; Zaid MA; Abonour R; Robertson M; Broxmeyer H; Oncotarget 2017 Nov 27
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Khawaja MR; Perkins SM; Schwartz JE; Robertson MJ; Kiel PJ; Sayar H; Cox EA; Vance GH; Farag SS; Cripe LD; Nelson RP Jr; American journal of hematology 2015 Feb
Khawaja MR; Perkins SM; Schwartz JE; Robertson MJ; Kiel PJ; Sayar H; Cox EA; Vance GH; Farag SS; Cripe LD; Nelson RP Jr; American journal of hematology 2015 Feb
Killer Cell Immunoglobulin-Like Receptor Ligand Mismatching: To Match or Mismatch?
Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Dec 10
Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Dec 10
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Vélez de Mendizábal N; Strother RM; Farag SS; Broxmeyer HE; Messina-Graham S; Chitnis SD; Bies RR; Clinical pharmacokinetics 2014 Mar
Vélez de Mendizábal N; Strother RM; Farag SS; Broxmeyer HE; Messina-Graham S; Chitnis SD; Bies RR; Clinical pharmacokinetics 2014 Mar
The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD; Farag SS; Expert opinion on investigational drugs 2014 Dec 13
Altenburg JD; Farag SS; Expert opinion on investigational drugs 2014 Dec 13
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
Davis T; Farag SS; International journal of nanomedicine 2013 Sep 16
Davis T; Farag SS; International journal of nanomedicine 2013 Sep 16
Differential stem- and progenitor-cell trafficking by prostaglandin E2.
Hoggatt J; Mohammad KS; Singh P; Hoggatt AF; Chitteti BR; Speth JM; Hu P; Poteat BA; Stilger KN; Ferraro F; Silberstein L; Wong FK; Farag SS; Czader M; Milne GL; Breyer RM; Serezani CH; Scadden DT; Guise TA; Srour EF; Pelus LM; Nature 2013 Mar 13
Hoggatt J; Mohammad KS; Singh P; Hoggatt AF; Chitteti BR; Speth JM; Hu P; Poteat BA; Stilger KN; Ferraro F; Silberstein L; Wong FK; Farag SS; Czader M; Milne GL; Breyer RM; Serezani CH; Scadden DT; Guise TA; Srour EF; Pelus LM; Nature 2013 Mar 13
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.
Farag SS; Srivastava S; Messina-Graham S; Schwartz J; Robertson MJ; Abonour R; Cornetta K; Wood L; Secrest A; Strother RM; Jones DR; Broxmeyer HE; Stem cells and development 2013 Feb 15
Farag SS; Srivastava S; Messina-Graham S; Schwartz J; Robertson MJ; Abonour R; Cornetta K; Wood L; Secrest A; Strother RM; Jones DR; Broxmeyer HE; Stem cells and development 2013 Feb 15
The potential role of Aurora kinase inhibitors in haematological malignancies.
Farag SS; British journal of haematology 2011 Oct 8
Farag SS; British journal of haematology 2011 Oct 8
From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
Zhang S; Farag SS; Expert opinion on investigational drugs 2011 May 26
Zhang S; Farag SS; Expert opinion on investigational drugs 2011 May 26
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
Farag SS; Maharry K; Zhang MJ; Pérez WS; George SL; Mrózek K; DiPersio J; Bunjes DW; Marcucci G; Baer MR; Cairo M; Copelan E; Cutler CS; Isola L; Lazarus HM; Litzow MR; Marks DI; Ringdén O; Rizzieri DA; Soiffer R; Larson RA; Tallman MS; Bloomfield CD; Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011 Jun 21
Farag SS; Maharry K; Zhang MJ; Pérez WS; George SL; Mrózek K; DiPersio J; Bunjes DW; Marcucci G; Baer MR; Cairo M; Copelan E; Cutler CS; Isola L; Lazarus HM; Litzow MR; Marks DI; Ringdén O; Rizzieri DA; Soiffer R; Larson RA; Tallman MS; Bloomfield CD; Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011 Jun 21
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP Jr; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR; Leukemia 2011 Jan 21
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP Jr; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR; Leukemia 2011 Jan 21
Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
Pelus LM; Farag SS; Stem cells and cloning : advances and applications 2011 Feb 27
Pelus LM; Farag SS; Stem cells and cloning : advances and applications 2011 Feb 27
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP Jr; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Oct 20
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP Jr; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Oct 20
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS; British journal of haematology 2010 Jun 15
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS; British journal of haematology 2010 Jun 15
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Nelson RP Jr; Yu M; Schwartz JE; Robertson MJ; Hromas R; Fausel CA; Vance GH; Dlouhy SR; Baute JA; Cox EA; Wood LL; Srivastava S; Robertson KA; Haut PR; Farag SS; Abonour R; Cornetta K; Cripe LD; Bone marrow transplantation 2010 Jan 11
Nelson RP Jr; Yu M; Schwartz JE; Robertson MJ; Hromas R; Fausel CA; Vance GH; Dlouhy SR; Baute JA; Cox EA; Wood LL; Srivastava S; Robertson KA; Haut PR; Farag SS; Abonour R; Cornetta K; Cripe LD; Bone marrow transplantation 2010 Jan 11
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP Jr; Cornetta K; Fausel CA; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Dec 4
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP Jr; Cornetta K; Fausel CA; Farag SS; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Dec 4
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Zhang S; Suvannasankha A; Crean CD; White VL; Chen CS; Farag SS; International journal of cancer. Journal international du cancer 2010 Dec 1
Zhang S; Suvannasankha A; Crean CD; White VL; Chen CS; Farag SS; International journal of cancer. Journal international du cancer 2010 Dec 1
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
Farag SS; Zhang S; Jansak BS; Wang X; Kraut E; Chan K; Dancey JE; Grever MR; Leukemia research 2009 Mar 3
Farag SS; Zhang S; Jansak BS; Wang X; Kraut E; Chan K; Dancey JE; Grever MR; Leukemia research 2009 Mar 3
Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 15
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 15
OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Aug 15
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Aug 15
Stem cell transplant, multiple myeloma
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.